

**I. Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-17. (cancelled)

Claim 18. (currently amended) A method for producing an immune response in humans ~~or animals~~, said method comprising the steps of:

(a) inserting a suppository into a urogenital orifice of a human, wherein said suppository comprises a vaccine or vaccine adjuvant(s) of microbial pathogens, capable of producing humoral or cellular-mediated immunity against urogenital disease in humans and a suppository base, wherein the suppository base comprises ~~pharmaceutically acceptable amounts of~~ about 98% of polyethylene glycol and about 2% of polysorbate; and

(b) contacting the suppository with mucosal tissue at and internal to the urogenital orifice to facilitate transfer of the vaccine or vaccine adjuvant material therethrough and induce an immune response in the human.

Claims 19-21 (cancelled)

Claim 22. (Currently amended) ~~The suppository-based delivery system method of claim 7 which~~ 18, wherein said suppository further comprises thimersol as a preservative.

Claims 23-25. (Cancelled)

Claim 26. (Previously presented) The method of claim 18, wherein said urogenital orifice is a vagina.

Claim 27-31 (Cancelled)

Claim 32. (New) The method of claim 18, wherein said urogenital disease is a urinary tract infection.

Claim 33. (New) A suppository for induction of an immune response in humans, said suppository comprising:

(a) a vaccine or vaccine adjuvant(s) of microbial pathogens, capable of producing humoral or cellular-mediated immunity against urogenital disease in humans and

(b) a suppository base comprising about 98% of polyethylene glycol and about 2% of polysorbate;

said suppository adapted to be inserted into the urogenital orifice of a human such that when the suppository is in contact with the tissues of the urogenital orifice transfer of the vaccine or vaccine adjuvant is facilitated therethrough.

Claim 34. (New) The suppository of claim 33, wherein said suppository further comprises thimersol as a preservative.

Claim 35. (New) The suppository of claim 33, wherein said urogenital orifice is a vagina.

Claim 36. (New) The suppository of claim 33, wherein said urogenital disease is a urinary tract infection.